Hu­mi­ra biosim­i­lar launch­es may serve as a test case for wider in­vest­ments, Biosim­i­lars Fo­rum leader cau­tions

Any com­par­isons be­tween Ab­b­Vie’s multi­bil­lion-dol­lar-per-quar­ter Hu­mi­ra (adal­i­mum­ab) and its biosim­i­lar mar­ket, and the block­buster in­sulins’ biosim­i­lars mar­ket can sim­ply point to the need for two …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER